Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
复制标题
DOI：
10.1111/dom.12660
复制
发表时间：
2016-06
期刊：
影响因子：
--
通讯作者：
Fernández Landó L
中科院分区：
文献类型：
--
作者：
Umpierrez GE;Pantalone KM;Kwan AY;Zimmermann AG;Zhang N;Fernández Landó L
通过分析来自6项头对头III期AWARD临床试验的数据，评估杜冷丁治疗患者的体重变化与糖化血红蛋白（HbA 1c）变化之间的关系。在26周时，由于设计和背景治疗的差异，在每项试验中分析体重和HbA 1c之间的关系，而不是通过汇总数据进行分析。还评价了基线特征对体重和HbA 1c反应的影响。在这些研究中，分别有87-97%和83-95%的患者接受1.5和0.75 mg的dullipin治疗，HbA 1c水平降低，而分别有57-88%和43-84%的患者接受1.5和0.75 mg的dullipin治疗，体重减轻。大多数（55-83%）接受1.5 mg dulplatin治疗的患者体重减轻，HbA 1c降低，而dulplatin 0.75 mg组中41-79%的患者体重减轻，HbA 1c水平降低。在接受dullipid治疗的患者中，观察到体重变化与HbA 1c（范围为-0.223至0.267）之间存在微弱且不一致的相关性。性别、年龄、糖尿病病程、HbA 1c、体重和BMI等基线特征与体重和HbA 1c反应的不同组合无关。Dulcantine是2型糖尿病治疗谱中的一种有效治疗选择。糖皮质激素对体重减轻和HbA 1c降低均表现出剂量依赖性效应。这些影响具有弱相关性，并且似乎是独立的。
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide‐treated patients by analysing data from six head‐to‐head phase III AWARD clinical trials. At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy. The effect of baseline characteristics was also evaluated with regard to weight and HbA1c response. Across the studies, 87–97% and 83–95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57–88% and 43–84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss. The majority (55–83%) of patients receiving dulaglutide 1.5 mg experienced weight loss and HbA1c reductions, while 41–79% of patients in the dulaglutide 0.75 mg arm lost weight and had reductions in HbA1c level. A weak and inconsistent correlation was observed between the changes in weight and HbA1c (range from −0.223 to 0.267) in patients treated with dulaglutide. The baseline characteristics of gender, age, duration of diabetes, HbA1c, body weight and BMI were not related to different combinations of weight and HbA1c responses. Dulaglutide is an effective treatment option across the type 2 diabetes treatment spectrum. Dulaglutide showed dose‐dependent effects on both weight loss and HbA1c reduction. These effects had a weak correlation and appeared to be independent.